Abstract Purpose: An open-label, multicenter, phase II study was conducted to define the safety and antitumor activity of the monoclonal antibody SGN-30 in patients with CD30 +
thology, they have different clinical presentations (1, 2, 5) . LyP lesions are small pink or red papules (≤2.0 cm) that regress spontaneously in 3 to 4 months without therapy, whereas pc-ALCL is characterized by larger tumors (>2 cm) that may not spontaneously regress. A subset of patients with transformed mycosis fungoides (T-MF) also has either LyP papules or tumors expressing CD30 (6, 7) . Because there are overlapping clinical presentations and patients may have more than one type of lesion, pc-ALCL and LyP are considered to be on a spectrum of CD30 + lymphoproliferative disorders (1) . Unlike systemic ALCL, pc-ALCL and LyP tend to have a favorable prognosis; however, the development of T-MF has an unfavorable prognosis, regardless of CD30 expression (3) . A recent study reported that multiple, nonidentical T-cell clones bearing a restricted T-cell repertoire were identified from 84% of skin lesions and from blood in 42% of patients with CD30
+ lymphoproliferative disorders, suggesting chronic antigen stimulation as a possible etiology for the disorder (8) .
For patients with pc-ALCL or LyP, it is difficult to induce complete remissions because new lesions reappear, especially after chemotherapy (1, 2, 4) . For patients with single or localized ALCL tumors, local radiotherapy is often the treatment of choice and is effective but it does not prevent new lesions from emerging. Although individual LyP lesions are typically selflimited, multiple lesions frequently occur and scarring is often present. Generalized LyP can be treated with PUVA, IFN-α, or low-dose oral methotrexate, but when therapy is stopped, the condition generally recurs (1) . Patients with multiple ALCL tumors or with T-MF are usually treated with oral bexarotene, denileukin diftitox (9, 10), oral methotrexate, or single-agent chemotherapy such as gemcitabine or Doxil (11) . More effective therapeutic options are needed that have improved toxicity profiles and are capable of inducing more durable responses.
CD30 or the Ki-1 antigen (12) is a cell surface leukocyte activation antigen expressed on several malignancies, including Hodgkin's lymphoma, ALCL, CTCL, Kaposi's sarcoma, a fraction of diffuse large B-cell lymphomas, some follicular lymphomas, and other lymphoproliferative diseases (13) (14) (15) (16) . Although the function of CD30 has not been clearly defined, it has been implicated in both cell death and proliferation (17) . In the normal physiologic state, CD30 cell surface expression is limited to activated T, B, and natural killer lymphocytes. Because CD30 serves as a diagnostic marker for the CD30 lymphoproliferative disorders, has a limited expression profile on normal cells and tissues, and has apoptosis-inducing characteristics, it has been evaluated as a target for immunotherapy (17, 18) . SGN-30 is a chimeric form of a novel murine monoclonal antibody, AC10, with specificity for CD30 that is distinct from other anti-CD30 antibodies (17) . The antitumor activity of SGN-30 has been extensively investigated in preclinical and clinical studies (17, 18) . In preclinical studies, SGN-30 induced growth inhibition of Hodgkin's lymphoma and ALCL cell lines in vitro and has shown potent antitumor activity in xenograft models of disseminated and localized Hodgkin's lymphoma and ALCL (17) . In a single-dose, phase I, dose-escalation clinical study in patients with CD30 + malignancies, SGN-30 was well tolerated, with no grade 3 nonhematologic or hematologic toxicities at doses up to 15 mg/kg, and evidence of antitumor activity was observed (18) . In a second open-label, phase I/II trial in patients with CD30
+ malignancies, patients tolerated up to six weekly doses of 12 mg/kg SGN-30 with no dose-limiting toxicities; one complete response (CR) was reported and stable disease (SD) was achieved in patients treated at each dose level.
The purpose of this study was to obtain preliminary antitumor activity and safety data for SGN-30 in the most common CD30-expressing cutaneous diseases: pc-ALCL, LyP, and T-MF.
Materials and Methods
Patients. Eligible patients were adults ages ≥18 y with a biopsyproven diagnosis based on a combination of histologic and clinical criteria. Patients had at least one of the following diagnoses: (a) primary cutaneous CD30 + ALCL (pc-ALCL) without systemic involvement (i.e., skin lesions present ≥1 mo without spontaneous regression with no nodal or visceral organ involvement, confirmed by computed tomography and/or positron emission tomography and bone marrow biopsy), (b) CD30 + LyP that was symptomatic and required systemic therapy, or (c) CD30
+ large cell transformation of mycosis fungoides (T-MF) without systemic involvement. Patients with palpable regional peripheral lymph nodes were eligible for enrollment only if a lymph node biopsy was negative for tumor.
Eligibility criteria included histologically confirmed CD30 + skin lesions within 3 mo of enrollment, failure to respond to local radiation therapy or to systemic therapy with a single agent (e.g., methotrexate or bexarotene) or with multiagent chemotherapy [e.g., CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)], and eligible for systemic therapy as determined by the investigator. A 3-wk washout from previous treatments was required, unless it was not in the best interest of the patient in the opinion of the investigator. Individual cases were discussed with the medical monitor before enrollment, and four waivers were granted: one patient was allowed a 5-d washout period due to worsening disease, two patients were allowed to continue ongoing medications (clobetasol and methotrexate), and one patient was granted a waiver at the investigator's discretion (no reason provided). Lesiondirected topical treatment for non-CD30 + skin lesions could be continued. All patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2, with a life expectancy of at least 6 mo. The following baseline laboratory results were required for study entry: absolute neutrophil count ≥1,000/mm 3 , platelet count ≥75,000/mm 3 , serum bilirubin ≤1.5 times upper limit of normal (ULN), serum creatinine ≤1.5 times ULN, blood urea nitrogen ≤1.5 times ULN, aspartate aminotransferase ≤2.5 times ULN, and alanine aminotransferase ≤2.5 times ULN. Females of childbearing potential must have had a negative β human chorionic gonadotropin pregnancy test result within 3 d of enrollment, and all patients agreed to use an effective contraceptive method during the course of the study.
Patients with Sézary syndrome (blood involvement with >1,000 atypical cells) or any type of lymphoproliferative disease other than pc-ALCL, LyP, or T-MF, or systemic ALCL or extracutaneous involvement of cutaneous ALCL were excluded. Patients were excluded if they had been treated previously with any anti-CD30 antibody or had a known hypersensitivity to recombinant proteins or any excipient contained in the drug formulation. They were also excluded for a positive history of another malignancy during the past 5 y (except adequately treated basal or squamous cell skin cancer or cervical carcinoma in situ) or for a known systemic viral, bacterial, or systemic fungal infections, or were seropositive for HIV or hepatitis B or C. Patients with symptomatic cardiac disease, including ventricular dysfunction, coronary artery disease, or arrhythmias, as well as any serious medical condition, were excluded if the investigator judged these would interfere with assessment of the safety or antitumor activity of the study drug. Patients with dementia or altered mental status that would preclude understanding and rendering of informed consent were excluded. Females were excluded if they were pregnant or breast-feeding.
Study design and schedule. This was an open-label, phase II multicenter study to define the safety profile and assess the antitumor activity of SGN-30 in patients with pc-ALCL and other closely related lymphoproliferative disorders (LyP and T-MF). The study was conducted from September 2004 to March 2007 at five study centers in the United States. The first six patients enrolled received six doses (one course) of SGN-30 at 4 mg/kg administered as an i.v. infusion every 2 to 3 wk. If there was no response, the dose could be increased to 12 mg/kg. A protocol amendment increased the starting dose to 12 mg/kg, which was received by 17 patients. Eligible patients could receive two additional six-dose courses of SGN-30.
Responses to therapy were evaluated with a Physicians Global Assessment (PGA) based on body surface area involvement in skin.
Translational Relevance
The spectrum of CD30 lymphoproliferative disorders includes lymphomatoid papulosis (self-regressing papules) and anaplastic large cell lymphoma. CD30 is a member of the tumor necrosis factor receptor family expressed in lymphocytes activated by viral infections, Reed Sternberg cells, lymphomatoid papulosis, anaplastic large cell lymphoma, and transformed mycosis fungoides. Because its expression in normal cells is limited, CD30 is an attractive molecule for targeted therapy. In this clinical trial, we have shown that the SGN-30 monoclonal antibody was well tolerated and clinically active for CD30 + lymphoproliferative disorders.
The first response evaluation was after two doses of study drug, at which time patients were assigned to one of three treatment courses:
1. Patients with SD or progressive disease (PD) could shorten the dosing interval to once every 2 wk and continue for up to four more doses. If their disease continued to progress following this scheduling change, they were discontinued from the study unless the investigator assessed some clinical benefit. After the response evaluation following the sixth dose, a decision was made about additional treatment with up to 12 more doses (two courses). If the patient had not had at least some improvement from baseline (improvement in the PGA), a discussion was held between the investigator and the sponsor before continuing treatment.
Patients who obtained a partial response (PR) after the first two doses
continued on the every-3-week schedule for a further four doses. Following the response assessment after the sixth dose, additional treatment was permitted, with up to 12 more doses (two courses).
3.
Patients who obtained a CR before the sixth dose, or subsequently in the extension phase, received two more doses of SGN-30 and then proceeded to follow-up. If there was progression within 12 mo of the last dose, they could receive additional doses of SGN-30 up to a maximum total of 18 doses (three courses).
Patients were allowed to have more than one type of clinical lesion (i.e., LyP and pc-ALCL or LyP and T-MF), but the primary disease assessments were made on only one of the skin lesion types, and dosing decisions were made based on response in the corresponding lesions.
Thus, if pc-ALCL was the primary diagnosis, the response assessment of pc-ALCL guided treatment decisions for the patient, although response assessment of the concomitant LyP was also documented. If the addition of a systemic treatment for a coexistent disease was required, the patient was discontinued from study treatment.
Safety assessments included adverse events, clinical laboratory evaluations including immunogenicity testing, and assessment of immunocompetence. Index lesions were measured in three dimensions and were the primary data source. Objective tumor response (CR or PR) was assessed based on change in tumor burden and PGA. Photographs of global and index lesions were taken throughout the study. If the size on the corresponding photograph seemed different from the reported measurement, the nonphoto measurement took priority. Quality of life (QOL) was assessed using the Functional Assessment of Cancer Therapy instrument (19, 20) and a patient self-assessment questionnaire.
The study was conducted according to the Declaration of Helsinki and the International Conference on Harmonization Tripartite Guideline on Good Clinical Practice. Approval from each center's appropriate research ethics committee was obtained. All patients signed written informed consent before participating.
Study end points. The primary end point for antitumor activity was the percentage of patients whose best clinical response during the observation period was a CR or PR. Time to response, duration of response following the last dose of SGN-30, progression-free and overall survival, and change from baseline in performance status and QOL † One patient in the 4 mg/kg group had pc-ALCL and LyP. In the 12 mg/kg group, two patients had LyP and T-MF; one patient had pc-ALCL and LyP; one patient had pc-ALCL, LyP, and T-MF; and one patient had LyP and past history of pc-ALCL.
also were measured. Safety end points included the toxicity profile and immunogenicity of SGN-30 in patients with pc-ALCL, LyP, or T-MF. Statistical analysis. An original sample size of 40 patients (of which 35 would be evaluable) was anticipated based on prior experience with SGN-30; however, due to sponsor decision to discontinue the corporate development of SGN-30, the trial was terminated after 23 patients had enrolled. The initial study design was to dose the first 20 patients starting at 4 mg/kg SGN-30, with the next 20 patients enrolled at an optional dose level of 12 mg/kg dependent on clinical response at the lower dose. Based on preliminary responses in the first 11 patients, a protocol amendment allowed further patients to start at 12 mg/kg of SGN-30.
The primary analysis data set for antitumor activity was the intentto-treat (ITT) population, which included all patients who received at least one dose of SGN-30 and had at least one assessment of tumor status after baseline. Tumor thickness (mm), tumor surface area (mm 2 ), number of LyP lesions, and PGA were collected at baseline, at each dose evaluation visit, at the end-of-treatment (EOT) visit (within 2 wk of final infusion), and at the follow-up visit (4 wk after EOT visit for patients with SD). The PGA was converted to CR, PR, SD, or PD using the following PGA definitions: CR, completely clear; PR, almost clear, marked improvement, or moderate improvement; SD, slight improvement or no change; PD, >25% worse than baseline. Summary of the best clinical response (CR, PR, SD, or PD) was provided for each study group and the total using the ITT population. The two-sided 95% confidence interval was constructed using the exact method. Patients who discontinued early from the study without achieving a CR or PR and patients for whom a response could not be confirmed were assumed to be nonresponders.
The ITT population also was used for safety assessments, which included summaries of all adverse events, grade 3 or 4 adverse events, serious adverse events (SAE), clinically significant laboratory values, and vital signs. The National Cancer Institute Common Toxicity Criteria for Adverse Events, version 3.0, was used to grade adverse events. Only treatment-emergent adverse events, defined as events with onset on or after the first dose of study drug, were of interest. 
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Results
Patients. A total of 23 patients were enrolled. Eleven patients had a primary diagnosis of pc-ALCL, 3 each had either LyP or T-MF, and 6 had mixed lesions compatible with LyP, pc-ALCL, and CD30 + MF (Table 1) . The majority of patients were Caucasian (87%), 15 (65%) were males, and the median age was 63 (range, 32-79 years); 13 patients (57%) were ≥60 years old. Most patients (87%) had an ECOG score of 0 at time of study entry. Patients were heavily pretreated: 96% had received prior systemic therapy regimens and 57% had received prior radiation therapy.
Six pc-ALCL patients enrolled under the original protocol and received an initial dose of 4 mg/kg; of these six patients, one discontinued due to disease progression after one dose and the other five patients' doses were later escalated to 12 mg/kg because of initial lack of response (Fig. 1) . After the first 11 patients had been treated in the study, an interim analysis was conducted. One patient had achieved a CR, five patients had achieved a PR, three patients had SD, and two patients had progression. After discussion with the principal investigators, the study protocol was amended to enroll all additional patients at the higher 12 mg/kg dose level of SGN-30. A total of 17 patients received SGN-30 at the higher 12 mg/kg starting dose. Overall, 7 patients received more than one course of SGN-30, and 14 patients completed the EOT assessments; 9 patients discontinued without completing EOT assessments.
Best clinical response. All 23 patients were evaluable for clinical response. The overall objective response rate (CR + PR) was 70% (16 of 23 patients). Ten patients (43%) achieved a CR, and another 6 patients (26%) achieved a PR (Table 2 ). In the pc-ALCL group, six patients (55%) achieved a CR and three (27%) achieved a PR. In the LyP group, one patient (33%) achieved a CR and another (33%) a PR. In the T-MF group, one patient (33%) achieved a PR. In patients with multiple diagnoses, three patients (50%) achieved a CR and another (17%) achieved a PR (Table 2) .
Overall clinical benefit of SGN-30, as assessed by achieving a response to therapy or SD (CR + PR + SD) during the study, was shown in 87% of patients (20 of 23) , including all patients with pc-ALCL or LyP and two thirds of patients with T-MF or a combination of lesion types. Only one patient in the T-MF group and two patients with multiple diagnoses had a best response of progressive disease during the study.
Duration of response. The overall median duration of objective response (CR + PR) was 84 days (range, 1-238 days); however, observations were censored for ∼70% of patients because longterm follow-up evaluations were not done consistently. Nine of the 10 patients who achieved a CR and 5 of the 6 patients who achieved a PR were in remission at their EOT or follow-up evaluation. Three of the six patients (all in the pc-ALCL group) whose dose of SGN-30 was originally 4 mg/kg and was increased to 12 mg/kg during the study achieved and maintained a CR or PR.
Overall survival. Time to progression, overall survival, and progression-free survival were secondary end points of the study (Fig. 2) . One 80-year-old patient, whose response is shown in Fig. 3A and B, expired from an unrelated myocardial infarction while on treatment; the remainder of the patients were alive at follow-up.
Illustrative case reports of response to SGN-30. The following case reports from the investigators provide additional follow-up information beyond what was formally collected in the study data base.
A 63-year-old male with a 2-year history of regressing papules developed new skin tumors interpreted as CTCL, T-MF on the face and chest without systemic involvement. New tumors appeared on the face and chest after treatment with local radiation, oral bexarotene, and intralesional steroid and IFN injections. He did not tolerate bexarotene due to diabetes and hypertriglyceridemia. Figure 3C Figure 3F and H shows A and B, response of multiple pc-ALCL tumors on the leg of an 80-year-old male with known aortic stenosis and coronary artery disease who had previously been treated with two courses of CHOP and local radiation before receiving SGN-30 for 18 mo. The patient expired from an unrelated myocardial infarction. C and D, T-MF lesions at baseline (C) and after 6 mo (D) of SGN-30 on the chest of a 63-year-old male with a 2-y history of regressing papules and multiple therapies (local radiation, oral bexarotene, and intralesional steroid and interferon injections) for new tumors. All of his lesions resolved and his CTCL has been in a complete response for 3 y. E -H, a 67-year-old male with history of pc-ALCL beginning in 1981 received multiple treatments, including local excision, local radiation, CHOP (six cycles), R-CVP chemotherapy, tipifarnib (a farnesyl transferase inhibitor), IV pentostatin, high-dose methotrexate (nine courses), gemcitabine, doxil, denileukin diftitoxin, and Campath H. E (arm) and G (back) are baseline photos of the patient's tumors before his treatment with SGN-30. F and H show growth of tumors on lower back and regression of tumors on upper arm, i.e., a mixed response in this highly pretreated refractory pc-ALCL patient. I and J, a 54-year-old female with a history of pc-ALCL ankle tumor treated in 1999 with CHOP and local radiation, began experiencing crops of pink papules (LyP) in 2001 that regressed spontaneously. She received one dose of 12 mg/kg of SGN-30, which was followed by an outbreak of LyP lesions on the thigh and upper arms (I and J). After that first infusion, her LyP unexpectedly remained in remission for 3 y.
growth of tumors on his lower back and regression of tumors on upper arm (i.e., a mixed response in this highly pretreated refractory pc-ALCL patient).
Three patients (at three different study centers) had a primary diagnosis of active LyP or LyP and pc-ALCL and had discontinued methotrexate before study entry. All were noted to have a flare of their LyP after one course of SGN-30. As an example, a 54-year-old female with a tumor of pc-ALCL on the ankle in 1999 was treated with CHOP and local radiation. In 2001, she began experiencing crops of pink papules (LyP) that regressed spontaneously. Although oral bexarotene seemed to decrease the lesions, she experienced dose-limiting hyperlipidemia. She received one dose of 12 mg/kg of SGN-30, which was followed by an outbreak of new LyP lesions on the thigh and upper arms ( Fig. 3I and J) . However, after that first infusion and flare, her LyP has been quiescent for 3 years and remains in remission. Although she was assessed as having PD and discontinued from the study because of the LyP flare, she actually has had an almost complete and long-lasting remission. A similar LyP patient had been methotrexate dependent since 1991 and also developed an unusual flare after her first dose of SGN-30; she was placed back on methotrexate, tapered off within a month, and remained lesion-free at study end without further treatment.
ECOG performance status and QOL assessment. Patients' ECOG performance status was measured at baseline and after each course of treatment. The majority (78%) had no change from baseline in ECOG performance status during the study. QOL for each patient was assessed using the Functional Assessment of Cancer Therapy instrument (19, 20) . Because of the small patient sample available, results were inconclusive.
Safety. Overall, 15 of 23 patients (65%) experienced at least one adverse event of any cause during the study; the most common were fatigue (22%) and diarrhea (17%; Table 3 ). No acute infusion reactions were associated with SGN-30 treatment. Most adverse events were mild or moderate. Only three patients experienced a grade 3 or 4 adverse event, and two grade 4 events occurred in the same patient, described below. Grade 3 events that were reported during the study included disease progression, skin infection, and pruritus in one patient; hypokalemia in another patient; and fatigue in a third patient. None of the grade 3 or 4 events was considered by the investigator to be related to study drug. One death occurred on the study; an 80-year-old male with multiple tumors of the leg (Fig. 3A and B) had known coronary artery disease, hypertension, and aortic stenosis and died from an unrelated myocardial infarction that was not aggressively treated. No other SAEs, hypersensitivity events, or allergic reactions were reported during the study.
Laboratory values were generally within the reference range and variation expected, given this patient population. No myelosuppression was observed.
Discussion
Cell surface antigens with expression largely restricted to malignant tumor cells offer the opportunity to ablate cancer cells selectively and potentially decrease overall toxicity of treatment. Several approaches have been used, including antibodies, fusion proteins, and small molecules. Monoclonal antibodies have been successfully directed against surface proteins; examples include rituximab, with specific binding to CD20 on B cells (21) , and cetuximab, which targets the epidermal growth factor receptor present on many epithelial tumors (22) . Because few definitive treatment options are available for patients with refractory or recurrent CD30 + hematologic malignancies, this surface receptor, with normal cell distribution restricted to <1% of circulating cells (e.g., activated leukocytes, including T cells, B cells, and macrophages), is an attractive tumor marker for targeted therapy (17) .
This study represents an exploratory trial to assess the safety and antitumor activity of SGN-30 treatment in heavily pretreated patients with CD30-expressing cutaneous lymphoproliferative diseases: pc-ALCL, LyP, or CD30 + T-MF. CD30 + skin lesions include self-regressing papules (LyP), larger nonregressing tumors (pc-ALCL), and transformed tumors found in patients with mycosis fungoides (T-MF; ref. 1). Thus, differentiation among Abbreviation: CTC, Common Toxicity Criteria. *One patient had grade 3 hypokalemia and grade 4 pneumonia and acute myocardial infarction; another patient had grade 3 disease progression, skin infection, and pruritus; a third patient had grade 3 fatigue. † One patient died after two SAEs (pneumonia and acute myocardial infarction); both of which were considered by the investigator to be unrelated to study drug.
these forms of CTCLs requires clinical correlation; as illustrated by this study, it is not uncommon to find one or more types of lesion occurring in the same patient. Although treatment options are available for patients with CD30 + or CD30 -CTCLs, most have either unacceptable toxicity or unfavorable response rates (≤50%) and must be given for prolonged intervals. Durable CRs in patients with active disease are rare. Although radiation often provides clinical benefit for isolated single tumors (1), it is of limited value for patients with widespread cutaneous tumors. Chemotherapy with CHOP or other agents may induce remissions of pc-ALCL lesions or short-term remissions in CD30 + LyP, but unfortunately, LyP lesions typically reemerge during or following chemotherapy.
As assessed by the five participating investigators in this study, treatment with SGN-30 was well tolerated and resulted in clinically meaningful CR or PR in 16 of the 23 patients (70%). There seemed to be a dose response: patients whose disease did not respond to 4 mg/kg SGN-30 achieved responses when the dose was increased to 12 mg/kg. Overall, 87% of patients obtained clinical benefit, defined as either CR or PR, or SD. Of interest, although three patients experienced flares in their LyP lesions following prestudy washout and their first infusion, each patient subsequently experienced clearing followed by long-lasting remission and disease-free survival (one patient for over 3 years). Withdrawing from methotrexate before therapy may have induced the transient tumor flares. Moreover, one patient who had been methotrexate dependent since 1991 was able to discontinue methotrexate and remain lesion-free for a prolonged interval. One patient with cutaneous T-MF and a history of LyP lesions achieved an ongoing, long-lasting CR.
To place these data in context, response rates of 69% to 80% have been observed with gemcitabine or pegylated liposomal doxorubicin for MF-CTCL tumors (11) , whereas the response rate of T-MF patients in this study was only 1 of 3 (33%). The clinical benefit of SGN-30 was similar to the response rate of 87% for low-dose oral methotrexate reported in 45 patients with symptomatic LyP, where 10 maintained prolonged responses after discontinuation; however, 5 of 10 patients who received methotrexate for >3 years had evidence of early hepatic fibrosis (23) . Documentation of multiple durable responses in the context of a well-tolerated outpatient treatment regimen suggests that approaches targeting the CD30 antigen may provide meaningful clinical benefit, especially for the CD30 + cutaneous lymphoproliferative disorders with favorable prognosis. In the current study, although 65% of patients had at least one adverse event, the most common was fatigue. Vomiting, neutropenia, and alopecia were not seen, and no evidence of liver damage was observed. Infusion reactions and cytokine release syndrome, reported with other antibodies, were not observed with SGN-30.
In conclusion, the promising overall response rates and safety profile observed in this study of patients with primary cutaneous CD30-expressing disorders provide proof of concept for therapeutically targeting the CD30 antigen to clear cutaneous lymphoproliferative disorders. 
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